Bioline Rx Stock Current Valuation
| BLRX Stock | ILS 7.70 0.40 4.94% |
Valuation analysis of BioLine RX helps investors to measure BioLine RX's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
Please note that BioLine RX's price fluctuation is relatively risky at this time. Calculation of the real value of BioLine RX is based on 3 months time horizon. Increasing BioLine RX's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since BioLine RX is currently traded on the exchange, buyers and sellers on that exchange determine the market value of BioLine Stock. However, BioLine RX's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 7.7 | Real 7.39 | Hype 7.7 | Naive 5.64 |
The real value of BioLine Stock, also known as its intrinsic value, is the underlying worth of BioLine RX Company, which is reflected in its stock price. It is based on BioLine RX's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of BioLine RX's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of BioLine RX helps investors to forecast how BioLine stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of BioLine RX more accurately as focusing exclusively on BioLine RX's fundamentals will not take into account other important factors: BioLine RX Company Current Valuation Analysis
BioLine RX's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current BioLine RX Current Valuation | (13.02 M) |
Most of BioLine RX's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, BioLine RX is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, BioLine RX has a Current Valuation of (13.02 Million). This is 100.09% lower than that of the Biotechnology sector and 100.28% lower than that of the Health Care industry. The current valuation for all Israel stocks is 100.08% higher than that of the company.
BioLine Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses BioLine RX's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of BioLine RX could also be used in its relative valuation, which is a method of valuing BioLine RX by comparing valuation metrics of similar companies.BioLine RX is currently under evaluation in current valuation category among its peers.
BioLine Fundamentals
| Return On Equity | -0.37 | |||
| Return On Asset | -0.2 | |||
| Current Valuation | (13.02 M) | |||
| Shares Outstanding | 922.87 M | |||
| Shares Owned By Insiders | 0.25 % | |||
| Shares Owned By Institutions | 0.10 % | |||
| Price To Book | 0.77 X | |||
| EBITDA | (25.37 M) | |||
| Net Income | (27.05 M) | |||
| Cash And Equivalents | 40.61 M | |||
| Cash Per Share | 0.28 X | |||
| Total Debt | 10.69 M | |||
| Debt To Equity | 23.20 % | |||
| Current Ratio | 5.12 X | |||
| Book Value Per Share | 0.08 X | |||
| Cash Flow From Operations | (23.57 M) | |||
| Earnings Per Share | (0.03) X | |||
| Target Price | 3.0 | |||
| Number Of Employees | 38 | |||
| Beta | 1.27 | |||
| Market Capitalization | 135.72 M | |||
| Total Asset | 81.39 M | |||
| Retained Earnings | (163 M) | |||
| Working Capital | 43 M | |||
| Current Asset | 46 M | |||
| Current Liabilities | 3 M | |||
| Z Score | 4.4 | |||
| Net Asset | 81.39 M |
About BioLine RX Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze BioLine RX's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BioLine RX using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BioLine RX based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in BioLine Stock
BioLine RX financial ratios help investors to determine whether BioLine Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in BioLine with respect to the benefits of owning BioLine RX security.